BTIG raised the firm’s price target on Insulet (PODD) to $310 from $300 and keeps a Buy rating on the shares after its Q4 earnings beat. The firm was impressed with the above-consensus outlook for International Omnipod, helped by entry into new countries and to a lesser extent, O5 pricing tailwinds, the analyst tells investors in a research note, adding that margins were also praiseworthy in the quarter.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet’s Strong Performance and Growth Potential: Analyst Recommends Buy Rating
- Insulet price target raised to $310 from $285 at Piper Sandler
- Insulet price target raised to $325 from $317 at Morgan Stanley
- Insulet price target raised to $324 from $304 at Canaccord
- Insulet price target raised to $355 from $310 at Citi